Since Friedrich Merz took office as Federal Chancellor on May 6, 2025, his government has been accused of systematically breaking election promises. The black-red coalition of CDU/CSU and SPD, formed under Merz's leadership, promised economic recovery, social stability, and a return to fiscal discipline during the election campaign. However, barely in office, Merz seems to have taken a different course: Massive debt accumulation, foreign policy prioritizing the Ukraine war, and neglect of the social sector have shaken the trust of many citizens. This analysis highlights Merz's key broken promises, examines why his policies neglect the social sector in Germany in favor of a foreign policy focus on Ukraine, and shows how these developments endanger democracy in Germany. The accusation that Merz's policies promote the erosion of democratic structures is substantiated by the analysis of loss of trust, social inequality, and political polarization. 1. Broken… 

The trade in reimported medicines in Germany is an economic sector that generates billions in revenue annually. Reimports – medicines manufactured in Germany, exported to other EU countries, and bought back at a lower price – promise savings for the healthcare system. However, while importers, wholesalers, and health insurance companies profit, patients face uncertainty, supply bottlenecks, and health risks. This report highlights the mechanisms of the reimport market, its economic incentives, and the serious consequences for patients. The Reimport Market: A Multi-Billion Dollar Business Drug reimportation exploits price differences within the EU. In countries like Spain, Italy, or Poland, medicines are often cheaper than in Germany because price regulation allows for lower margins. Importers such as kohlpharma, EMRAmed, or axicorp purchase these medicines, bring them back to Germany, and sell them at prices below those of the original preparations, but still profitable. Parallel imports – medicines that are imported directly from another EU country… 

Silver Spring, Maryland, June 27, 2025 – The U.S. Food and Drug Administration (FDA) has rescinded the Risk Evaluation and Mitigation Strategies (REMS) for currently approved BCMA- and CD19-directed autologous Chimeric Antigen Receptor (CAR) T-cell immunotherapies. This decision aims to facilitate access to these potentially life-saving therapies and reduce the burden on the healthcare system, as announced by the FDA on Thursday. The affected therapies, approved for treating blood cancers such as multiple myeloma, certain leukemias, and lymphomas, were previously subject to strict safety requirements due to the risks of cytokine release syndrome (CRS) and neurological toxicities. However, the FDA determined that the established management guidelines and the extensive experience of the medical community in diagnosing and treating these risks are sufficient to ensure safe use without REMS. “Rescinding REMS that are no longer required accelerates the delivery of potentially curative treatments… 

Washington, June 28, 2025 – The U.S. House of Representatives passed the controversial “One Big Beautiful Bill Act” on May 22, 2025, a budget bill that includes massive cuts to the social programs Medicaid and the Supplemental Nutrition Assistance Program (SNAP). According to a new analysis by the Commonwealth Fund and the George Washington University Milken Institute School of Public Health, these cuts could lead to a loss of 1.22 million jobs, a decrease in state gross domestic product (GDP) of $154 billion, and a loss of $12 billion in state and local tax revenue by 2029. The economic damage would significantly exceed the planned federal savings of $131 billion, particularly in poorer states. Cuts in focus: Medicaid and SNAP The bill proposes cuts of $863 billion to Medicaid and $295 billion to SNAP over a ten-year period (2025–2034). According to estimates…